Hematologic Malignancy
Acute Myeloid Leukemia
CI-CAN-00001674AML · ANLLExplore in graph →
Hematologic789 active trials18 approved drugs279 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001674AML · ANLLExplore in graph →
Clinical trials
2,964 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (536)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06928662 | Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse | recruiting | Phase 1 / Phase 2 | 36 | Fred Hutchinson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT06222580 | SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation | recruiting | Phase 1 | 30 | Uma BorateOTHER | 1 | May 14, 2026 |
| clinicaltrials |
| NCT07566377 | Cord Blood Transplantation in Children and Young Adults With Blood Cancer | recruiting | Phase 2 | 71 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07583888 | VABu Conditioning in Elderly AML HSCT | recruiting | Phase 2 / Phase 3 | 20 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT03844048 | An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial | active not recruiting | Phase 3 | 165 | AbbVieINDUSTRY | 23 | May 13, 2026 | clinicaltrials |
| NCT04067336 | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 263 | Kura Oncology, Inc.INDUSTRY | 7 | May 13, 2026 | clinicaltrials |
| NCT04314401 | National Cancer Institute "Cancer Moonshot Biobank" | active not recruiting | — | 1,600 | National Cancer Institute (NCI)NIH | 2 | May 13, 2026 | clinicaltrials |
| NCT05794880 | MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing | recruiting | N/A | 40 | Medical College of WisconsinOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06066242 | Optimizing Induction Chemotherapy Regimens for ND Elderly AML Patients Who Are Eligible for Intense Chemotherapy | active not recruiting | N/A | 113 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06611839 | Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML(IDH1-AML-2024) | recruiting | Phase 1 / Phase 2 | 23 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06635681 | Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML(DAV-AML-2024) | recruiting | Phase 2 | 380 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06744556 | HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML | active not recruiting | Phase 2 | 41 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07583303 | BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation | not yet recruiting | Phase 1 | 19 | City of Hope Medical CenterOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07584889 | Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies(CAR-p40-T) | recruiting | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT04801797 | Venetoclax + Azacitidine vs. Induction Chemotherapy in AML | active not recruiting | Phase 2 | 172 | Massachusetts General HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05583552 | Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy(IMpress) | active not recruiting | Phase 2 | 46 | GCP-Service International West GmbHINDUSTRY | 3 | May 12, 2026 | clinicaltrials |
| NCT07270978 | Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS(AML-MDS 001) | recruiting | Phase 1 | 23 | University of VirginiaOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05907057 | An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. | recruiting | Phase 3 | 245 | Servier Affaires MédicalesINDUSTRY | 4 | May 8, 2026 | clinicaltrials |
| NCT06323590 | Refining the Role of Mid-induction Bone Marrow Biopsy in Acute Myeloid Leukemia: A Pilot Study | active not recruiting | — | 60 | University of Alabama at BirminghamOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06928376 | A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients | recruiting | Phase 2 | 160 | Chinese PLA General HospitalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07243483 | Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute Myeloblastic Leukemia(EUREKA-VEN) | recruiting | N/A | 100 | Centre Leon BerardOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07572695 | Salvage Haploidentical HSCT With DLI and Targeted Therapy for R/R AML | not yet recruiting | — | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | May 7, 2026 | clinicaltrials |
| NCT03560882 | A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies | active not recruiting | Phase 1 | 50 | Joaquina BarandaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04872595 | A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant | active not recruiting | Phase 2 | 59 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04217278 | A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT(COSI) | active not recruiting | Phase 2 / Phase 3 | 333 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04771572 | Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. | recruiting | Phase 1 | 100 | Newave Pharmaceutical IncINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT04888741 | Methods of T Cell Depletion Trial (MoTD)(MoTD) | recruiting | Phase 2 | 400 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04977180 | Cardioprotection in AML(AML 001) | recruiting | Phase 2 | 70 | University of VirginiaOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07374029 | Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML | recruiting | Phase 1 | 30 | David AviganOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT04482894 | Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS | active not recruiting | N/A | 105 | University of VirginiaOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT07563920 | TBF Conditioning Regimen for Haploidentical Stem Cell Transplantation in Elderly AML Patients in First Complete Remission(TBF-AML) | not yet recruiting | N/A | 93 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | May 4, 2026 | clinicaltrials |
| NCT05833438 | Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy(VENAZA-5S) | active not recruiting | Phase 2 | 45 | University of LeipzigOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07551037 | Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy(AML) | recruiting | Phase 1 | 90 | Fujian Medical University Union HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07561892 | Study of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3).(AML) | recruiting | Phase 4 | 100 | Fujian Medical University Union HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562568 | SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS | not yet recruiting | Phase 2 | 160 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07563179 | Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04256317 | A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | recruiting | Phase 2 / Phase 3 | 316 | Taiho Oncology, Inc.INDUSTRY | 10 | Apr 30, 2026 | clinicaltrials |
| NCT06497062 | Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia | active not recruiting | Phase 2 | 47 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07420790 | Design and Validation of a Generative AI and Propensity Score Matching Model for the VEN-DEC Phase II Study in Elderly AML Eligible for Allo-SCT; Evaluation of an Exploratory Approach Respect to a Randomized Phase III Trial(VenDec-AI) | recruiting | — | 1,941 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06195891 | Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome | recruiting | Phase 1 | 33 | City of Hope Medical CenterOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT04898894 | Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | active not recruiting | Phase 1 | 37 | St. Jude Children's Research HospitalOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT01627041 | Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia | active not recruiting | Phase 2 | 178 | National Cancer Institute (NCI)NIH | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03178617 | High-Intensity Parent Intervention Program in Improving Learning and School Functioning in Latino Children With Acute Leukemia or Lymphoblastic Lymphoma | active not recruiting | N/A | 214 | City of Hope Medical CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05396859 | Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia | active not recruiting | Phase 1 | 13 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06129734 | Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant | recruiting | Phase 1 / Phase 2 | 20 | Benjamin TomlinsonOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07552649 | Matched Sibling Allogenic Stem Cell Transplantation With Adoptive Immunotherapy With Regulatory And Conventional T Cells For High Risk Acute Myeloid Leukemia(MATCH-Treg) | not yet recruiting | Phase 2 | 28 | Antonio PieriniOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03164057 | A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia | active not recruiting | Phase 2 | 206 | St. Jude Children's Research HospitalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03633955 | Pilot Imaging Study of Leukemia(REALIZE) | recruiting | Phase 1 | 60 | University of OklahomaOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05428969 | A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies(BEXMAB) | active not recruiting | Phase 1 / Phase 2 | 181 | Faron Pharmaceuticals LtdINDUSTRY | 3 | Apr 23, 2026 | clinicaltrials |
| NCT06816134 | Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia | recruiting | Phase 2 | 48 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Apr 23, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 15, 2026source: clinicaltrials